iBio (IBIO) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IBIO, but not buy additional shares or sell existing shares.
View IBIO analyst ratings or view top-rated stocks.

iBio saw a increase in short interest in August. As of August 31st, there was short interest totaling 296,700 shares, an increase of 6.1% from the August 15th total of 279,600 shares. Based on an average daily volume of 727,900 shares, the short-interest ratio is presently 0.4 days. Approximately 1.3% of the company's shares are short sold.
View iBio's Short Interest.

iBio, Inc. (NYSEAMERICAN:IBIO) issued its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($1.00) EPS for the quarter, beating analysts' consensus estimates of ($1.25) by $0.25. The biotechnology company had revenue of $0.21 million for the quarter.

iBio shares reverse split before market open on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

iBio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avantax Planning Partners Inc. (0.92%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Martin Brenner and Robert Matthew Lutz.
View institutional ownership trends.

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IBIO stock can currently be purchased for approximately $0.30.

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $5.06 million and generates $2.38 million in revenue each year.

The company employs 105 workers across the globe.

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173.